Time-From-Diagnosis Subgroups

POST HOC ANALYSIS: Time-from-diagnosis Subgroups 53% Risk Reduction of Disease Progression When UPTRAVI Used Within 6 Months of Diagnosis vs Placebo1-3

The information below is from a post hoc subgroup analysis of the GRIPHON trial.
View the GRIPHON pivotal data for context of the overall population.

Baseline patient characteristics*

  • GRIPHON patients were categorized based on their time from diagnosis at baseline using a 6-month threshold:
    • Patients treated earlier (time from diagnosis ≤6 months, n=404)
    • Patients treated later (time from diagnosis >6 months, n=752)
  • This threshold has previously been used to define newly diagnosed patients with PAH4
Time to first disease progression event (UPTRAVI vs placebo; time from diagnosis ≤6 months)
Patients treated
within 6 months of
PAH diagnosis
Time to first disease progression event (UPTRAVI vs placebo; time from diagnosis >6 months)
Patients treated
after 6 months of
PAH diagnosis
Events in patients treated within 6 months of PAH diagnosis1

Events in patients treated after 6 months of PAH diagnosis1

Adverse reactions in time-from-diagnosis subgroups notably different from overall population

  • Irrespective of time from diagnosis, the most frequently reported adverse reactions for patients treated with UPTRAVI were headache, diarrhea, and nausea3
  • No differences in safety profile were observed between the 2 subgroups3